Expression and production of the CXC chemokine growth-related oncogene-alpha by human eosinophils.
Eosinophils are seen together with neutrophils at sites of inflammation. However, their roles are not clear. In addition, eosinophils infiltrate tumor tissue in some neoplastic diseases. In this study, we show that large amounts of the neutrophil-activating CXC chemokine growth-related oncogene (GRO)-alpha can be produced by human eosinophils. Eosinophils showed presence of preformed GRO-alpha in the crystalloid-containing specific granules (190 pg/2 x 10(6) cells). During incubation, a strong increase in GRO-alpha gene expression was seen. At a low cell density, addition of TNF-alpha or IL-1 beta increased the production of GRO-alpha in eosinophils, which was not the case at a higher cell density. Eosinophils can produce TNF-alpha themselves, and neutralizing Abs against TNF-alpha significantly inhibited GRO-alpha production. This suggests that autocrine and paracrine effects from TNF-alpha can be important when up-regulating GRO-alpha gene expression. In contrast, IFN-gamma, a prototypic Th1-cytokine, down-regulated expression of GRO-alpha. This may be important during resolution of inflammation but also suggests different roles for eosinophils depending on the inflammatory context. Tumor-infiltrating eosinophils in Hodgkin's disease of the nodular sclerosing type are associated with a poor prognosis. Eosinophils from such tumor tissue showed an abundant expression of GRO-alpha. The GRO-alpha receptor CXCR2 was also detected in tumor tissue, proposing interactions between eosinophils and the tumor. Our findings suggest that eosinophils can promote inflammation through recruitment of CXCR2-bearing cells. In addition, this feature of the eosinophils indicates a role for these cells in the biology of certain tumors.
Department of Medical Microbiology, Lund University, Malmö University Hospital, Malmö, Sweden. Terese.Dajotoy@mikrobiol.mas.lu.se
Terese
T
Persson-Dajotoy
Pia
P
Andersson
Anders
A
Bjartell
Jero
J
Calafat
Arne
A
Egesten
D019898:Autocrine Communication / Q000502:physiology; D002450:Cell Communication / Q000502:physiology; D054360:Chemokine CXCL1; D018925:Chemokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D019743:Chemokines, CXC / Q000096:biosynthesis*; D002630:Chemotactic Factors / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D015536:Down-Regulation / Q000502:physiology; D004804:Eosinophils / Q000378:metabolism* / Q000502:physiology / Q000648:ultrastructure; D006689:Hodgkin Disease / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D036341:Intercellular Signaling Peptides and Proteins / Q000096:biosynthesis*; D007371:Interferon-gamma / Q000494:pharmacology; D015848:Interleukin-5 / Q000494:pharmacology; D016209:Interleukin-8 / Q000096:biosynthesis; D016253:Microscopy, Immunoelectron; D009363:Neoplasm Proteins / Q000096:biosynthesis; D019899:Paracrine Communication / Q000502:physiology; D006255:Rhinitis, Allergic, Seasonal / Q000378:metabolism / Q000473:pathology; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology; D015854:Up-Regulation / Q000502:physiology
C475829:CXCL1 protein, human; D054360:Chemokine CXCL1; D018925:Chemokines; D019743:Chemokines, CXC; D002630:Chemotactic Factors; D036341:Intercellular Signaling Peptides and Proteins; D015848:Interleukin-5; D016209:Interleukin-8; D009363:Neoplasm Proteins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma